Preventing disease in poultry with Zoetis Embrex@ In-Ovo Vaccination Technology
Zoetis, the world’s leading animal health company, is spearheading a transformative shift in the Indian poultry industry through the introduction of the innovative in-ovo vaccination with Embrex@ technology to vaccinate chickens for Marek’s disease and other poultry diseases, supporting early immune response or early chick immunity which results in newly hatched chicks with protection from disease challenges. India is the world’s third-largest egg producer and eighth- largest meat producer’, and boasts a highly organized poultry sector. The evolution from traditional practices to modern, organized methods has been facilitated by advancements such as the Embrex» In-Ovo Vaccination Technology.
The adoption of in-ovo vaccination in India commenced six years ago with the successful installation of Embrex@ Biodevices in leading integrators across the northern and central regions. Zoetis recognized the critical role of biosecurity and infrastructure challenges in the Indian poultry industry’s transformation. By addressing these challenges and overcoming the initial hurdles in technology adoption and operational integration, the industry has embraced in-ovo vaccination, leading to notable improvements in process optimization, biosecurity, and farm performance. Zoetis Embrex@ In-ovo Vaccination Technology has shown clear benefits in terms of disease management and stress-free vaccine administration.
Embrexs has established its dominance in the South Asian market (India, Bangladesh, Nepal & Sri Lanka), securing contracts for In-Ovoject devices in major hatcheries over six years and maintaining a 100% market share2. This dominance is reflected in the region’s impressive throughput of 700 eggs per minute through the Zoetis Embrex@ lnOvoject@ System2, underscoring its unparalleled efficiency and scalability. The exponential growth of this system underscores the significant impact Of In-Ovo Vaccination Technology on poultry health management to protect against disease.
Zoetis has been instrumental in advancing In-Ovo vaccination practices, aligning with the industry’s increasing automation. Since its commercial introduction in 1992, the Embrex@ Inovoject@ System has revolutionized poultry practices globally, with over 20 billion eggs vaccinated annually across more than 40 countries using in-ovo technology3.
In-ovo Technology involves the administration of various vaccines to poultry embryos during the incubation process. In- Ovo immunization offers biological and commercial advantages over subcutaneous vaccination, including up to100% site of injection (SOI)4 accuracy to chicken embryos at the age of 18 – 19 days of incubation, early immunity development, reduced bird stress, and optimized production outcomes. Research demonstrates that early placement facilitated by in-ovo vaccination improves bird health and producer profits5. Moreover, Embrex@ Biodevices help producers streamline operations by ensuring precise vaccine delivery, and significantly reducing labour requirements and the risk Of errors.
In summary, the widespread adoption of In-Ovo Technology in India and South Asia signifies a change in thinking in poultry health management, promoting efficiency, productivity, and sustainability. Hatcheries of varying sizes have switched to in ovo vaccination for reliable poultry vaccination in the hatchery to help support efficient hatchery processes and flock immunization — and to enjoy benefits that cascade across their operations. With a continuous flow of inquiries pouring in regarding Embrex@ In-Ovo Vaccination Technology, it is evident that people are recognizing the transformative potential of this cutting-edge technology. Zoetis’ ongoing commitment to advancing its purpose to nurture the world and humankind by advancing care for animals continues to position it as a key player in shaping the future of the Indian poultry industry.
